ライフサイエンスコーパス: carcinoma

1 inflammation (turpentine) and cancer (breast carcinoma).

2 5 in the progression of human hepatocellular carcinoma.

3 with abnormally high rates of hepatocellular carcinoma.

4 f a right axillary node confirmed metastatic carcinoma.

5 of the disease can progress to squamous cell carcinoma.

6 ations of liver cirrhosis and hepatocellular carcinoma.

7 itivity, and increased risk of squamous cell carcinoma.

8 icle-based drug delivery in murine pulmonary carcinoma.

9 f tumor entities such as pancreatic or colon carcinoma.

10 n hepatocytes, which leads to hepatocellular carcinoma.

11 grade, recurrent, platinum-sensitive ovarian carcinoma.

12 Tyr35Asn mutations in kidney and endometrial carcinoma.

13 ith non-high-grade DCIS will harbor invasive carcinoma.

14 ity, progeria and early onset hepatocellular carcinoma.

15 ee sentinel lymph nodes contained metastatic carcinoma.

16 s, and the in vitro invasive capacity of the carcinoma.

17 on of SBA with colorectal cancer and gastric carcinoma.

18 disease progression in clear cell renal cell carcinoma.

19 hypothyroidism, and esophageal squamous cell carcinoma.

20 in human actinic keratosis and squamous cell carcinoma.

21 rrhosis, hepatic failure, and hepatocellular carcinoma.

22 for the presence of IPMN-associated invasive carcinoma.

23 position events in high-grade ovarian serous carcinoma.

24 is one of the main causes of hepatocellular carcinoma.

25 d for use in adults with advanced basal-cell carcinoma.

26 melanoma, WT-GBM glioma and MKN45-P gastric carcinoma.

27 in patients with head and neck squamous cell carcinoma.

28 unresectable, liver-confined hepatocellular carcinoma.

29 4 might be a novel target of DACH1 in breast carcinoma.

30 patitis, liver cirrhosis, and hepatocellular carcinoma.

31 years and was diagnosed with nasopharyngeal carcinoma.

32 causes fibrosis/cirrhosis and hepatocellular carcinoma.

33 cient invasive transition zone squamous cell carcinoma.

34 y lead to liver cirrhosis and hepatocellular carcinoma.

35 tal cancer is the commonest gastrointestinal carcinoma.

36 prominent EVI1 effector mechanism in breast carcinoma.

37 and potential therapeutic strategy for oral carcinoma.

38 ted regression of established hepatocellular carcinoma.

39 es with poor clinical outcomes in renal cell carcinoma.

40 are frequent in head and neck squamous cell carcinomas.

41 a decisive role in malignant progression of carcinomas.

42 were not the same in the HER2-driven mammary carcinomas.

43 S mutations are present in 15-30% of thyroid carcinomas.

44 hibits strong correlations in primary breast carcinomas.

45 on (5% vs 11%; P< 0.0001) and development of carcinoma (1% vs 3%; P= 0.008).

46 minant component (41%), variants and special carcinomas (8%).

47 In renal cell carcinoma, 8 samples reduced the list of clonal alterati

48 n of local tumor recurrence after renal cell carcinoma ablation.

49 Pancreatic acinar cell carcinoma (ACC) is an aggressive exocrine tumor with lar

50 igated the role of RARRES2 in adrenocortical carcinoma (ACC), a rare lethal malignancy in which aberr

51 t curative intent surgery for adrenocortical carcinoma (ACC).

52 with lobular carcinoma vs those with ductal carcinoma (adjusted odds ratio, 1.44; 95% CI 1.06-1.95;

53 tumor recurrence in patients with renal cell carcinoma after thermal ablation.

54 cer and eight with large-cell neuroendocrine carcinoma, all of whom received at least one dose of rov

55 n kidney, and is downregulated in renal cell carcinoma; also, its low expression correlates with poor

56 adenocarcinoma, or esophageal squamous cell carcinoma.Among older American adults, both nut and pean

57 ologically verified; 80% were hepatocellular carcinoma and 20% were intrahepatic cholangiocarcinoma.

58 (HPV) infections cause nearly every cervical carcinoma and a subset of tumors in the oropharyngeal tr

59 s in lung adenocarcinoma, lung squamous cell carcinoma and breast carcinoma cancer cells.

60 splantation for patients with hepatocellular carcinoma and cirrhotic livers.

61 orly differentiated, grade 3 invasive ductal carcinoma and ductal carcinoma in situ (largest focus, 3

62 been studied for the treatment of pancreatic carcinoma and has shown a significant survival benefit.

63 analysis of public databases of human breast carcinoma and IHC analysis of mice xenograft tumors demo

64 rstanding of the correlation between thyroid carcinoma and LFS, tumor profile data of Brazilian carri

65 The proportions for malignant lesions (carcinoma and lymphoma; 27/76, 36%) and benign dacryoade

66 to immunotherapies, including hepatocellular carcinoma and ovarian adenocarcinoma, Gadd45b inhibition

67 ignaling, where Ptch1 loss causes basal cell carcinoma and Ptch1;Ptch2 loss disrupts skin and hair fo

68 elopment, psoriasis, cutaneous squamous cell carcinoma and re-epithelisation are highlighted.

69 cause of liver cirrhosis and hepatocellular carcinoma and the leading indication for liver transplan

70 expression profiling of Ccn6(fl/fl) mammary carcinomas and comparison of orthologous genes with a hu

71 shed new light into understanding of ovarian carcinomas and may provide a new therapeutic strategy fo

72 ICD) are frequently observed in ECs of human carcinomas and melanoma, and in ECs of the pre-metastati

73 as a consequence of a biopsy or due to renal carcinomas and postinflammatory changes.

74 e risk of human papillomavirus (HPV)-related carcinomas and premalignancies in women diagnosed with c

75 s shared proteomic features with gynecologic carcinomas and sarcomas with intermediate EMT features.

76 th PCLD, 18 240 patients with hepatocellular carcinoma, and 98 567 patients with CLF.

77 iteria were obstructive uropathy, urothelial carcinoma, and metastatic cancer.

78 atitis, pancreatic cancer, medullary thyroid carcinoma, and serious adverse events did not differ sig

79 arcinoma as compared with lung squamous cell carcinoma, and that neutrophils are the most prevalent i

80 Label free detection of the carcinoma antigen-125 was accomplished by differential v

81 nanowire for the ultrasensitive detection of carcinoma antigen-125.

82 ally verified primary head and squamous cell carcinoma at Odense University Hospital from September 2

83 ifferent cancer models: 4T1 and MCF-7 breast carcinoma, B16F10 melanoma, WT-GBM glioma and MKN45-P ga

84 e is aberrantly elevated in human basal cell carcinoma (BCC), coinciding with increased primary cilia

85 Basal cell carcinoma (BCC), the most common human cancer, results f

86 Human basal cell carcinomas (BCCs) very frequently carry p53 mutations, a

87 eater risk of developing numerous basal cell carcinomas (BCCs).

88 s-for patients diagnosed with hepatocellular carcinoma between Aug 1, 2006, and April 1, 2016, were e

89 significant inhibitory effects against colon carcinoma (CaCo-2) cells.

90 oma, lung squamous cell carcinoma and breast carcinoma cancer cells.

91 tients with EGFR FISH-positive squamous-cell carcinoma cancers are encouraging and support continued

92 tin-modifying genes in clear cell renal cell carcinoma (ccRCC) has been uncovered through next-genera

93 downregulated in human clear cell renal cell carcinoma (ccRCC) samples, which was also verified in se

94 Some cancers, such as clear cell renal cell carcinoma (ccRCC), require exogenous glutamine for growt

95 quitously expressed in clear cell renal cell carcinoma (ccRCC).

96 frequently mutated in clear cell renal cell carcinoma (ccRCC).

97 stood yet vital phenomenon, particularly for carcinoma cell invasion on aligned collagen fibres.

98 induced effects using a human hepatocellular carcinoma cell line, HepG2 cells.

99 the evaluation of IDO1 expression in thyroid carcinoma cells and for the study of involved signal tra

100 anisotropic constructs, we find that breast carcinoma cells are acutely sensitive to the direction a

101 trate that targeting MUC1-C in diverse human carcinoma cells downregulates EZH2 and other PRC2 compon

102 a4 integrin protects adherent epithelial and carcinoma cells from ferroptosis induced by erastin.

103 ells, and LU-HNSCC-25 head and neck squamous carcinoma cells in phosphate buffered saline.

104 s in human prostate cancer or hepatocellular carcinoma cells in vitro and in mouse xenografts.

105 well as extravasation following injection of carcinoma cells into the tail vein.

106 that PTEN deletion in HCT116 and DLD1 colon carcinoma cells leads to suppression of CHK1 and CHK2 ac

107 l that expression of IRS-2 sensitizes breast carcinoma cells to apoptosis in response to treatment wi

108 Knocking down Elmo1 impairs metastasis of carcinoma cells to the lung, thereby providing insights

109 atrices is observed for the subpopulation of carcinoma cells with high tumor initiating and metastati

110 n macrophages (MPhi) with human MCF-7 breast carcinoma cells, which caused cell death of cancer cells

111 TRAIL-mediated apoptosis in a panel of renal carcinoma cells.

112 constitutive ERK activity in HER2(+) breast carcinoma cells.

113 ic regions of tumor formed by nasopharyngeal carcinoma CNE2 cells and breast cancer MDA-MB-231 cells,

114 We show that migration of carcinoma collectives on fibrillar FN-rich matrices is a

115 inal orchiectomy, which disclosed testicular carcinoma composed of 90% choriocarcinoma, 9% seminoma,

116 herefore initiated an African hepatocellular carcinoma consortium aiming to describe the clinical pre

117 Carcinomas constitute over 80% of all human cancer types

118 Cutaneous squamous cell carcinoma (cSCC) is one of the most common metastatic sk

119 roposed for advanced cutaneous squamous cell carcinomas (cSCC); however, its efficacy is inconsistent

120 rmal and neoplastic (cutaneous squamous cell carcinoma, cSCC) human epidermal cells.

121 ed apoptosis in normal and benign but not in carcinoma cultures.

122 Embryonic carcinoma (EC) cells are malignant counterparts of embry

123 Human embryonic carcinoma (EC) cells are shown to restrict the expressio

124 ion study (GWAS) on esophageal squamous cell carcinoma (ESCC) in Han Chinese, we conducted a follow-u

125 hereby prevents cellular senescence, IPF and carcinoma formation.

126 ) T-cell ablation accelerates hepatocellular carcinoma, genetic or pharmacological interference with

127 arian, primary peritoneal, or fallopian tube carcinoma, had received at least two previous platinum-b

128 has anticancer activity in recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage

129 Renal cell carcinoma has long been understood to have a component o

130 ological effect of SDT on oral squamous cell carcinoma has not been studied.

131 with a decreased incidence of hepatocellular carcinoma (hazard ratio [HR] compared with patients with

132 ents with CLF from NASH), and hepatocellular carcinoma (HCC) (decreases in percentages of patients wi

133 intrahepatic recurrent small hepatocellular carcinoma (HCC) against the diaphragmatic dome.

134 rowing cause of cirrhosis and hepatocellular carcinoma (HCC) and increasingly an indicator for liver

135 increases early detection of hepatocellular carcinoma (HCC) and prolongs survival.

136 Patients with hepatocellular carcinoma (HCC) can receive Model for End-Stage Liver Di

137 s was also shown to attenuate hepatocellular carcinoma (HCC) development, thus implicating ATX/LPA in

138 llance by ultrasonography for hepatocellular carcinoma (HCC) for individuals with cirrhosis is recomm

139 of sorafenib in patients with hepatocellular carcinoma (HCC) has been undervalued due to the absence

140 integration events and human hepatocellular carcinoma (HCC) has generated controversy about the caus

141 he incidence and mortality of hepatocellular carcinoma (HCC) have been reported to be plateauing in t

142 pression of FAM83H and MYC in hepatocellular carcinoma (HCC) have been reported.

143 se also decreases the risk of hepatocellular carcinoma (HCC) in patients with chronic HBV and HCV inf

144 for noninvasive diagnosis of hepatocellular carcinoma (HCC) in patients with cirrhosis.

145 Whether there is a change of hepatocellular carcinoma (HCC) incidence in chronic hepatitis B patient

146 Hepatocellular carcinoma (HCC) is a common cancer that frequently overe

147 Hepatocellular carcinoma (HCC) is more prevalent in men than women, but

148 Hepatocellular carcinoma (HCC) is one of the most commonly diagnosed ca

149 Hepatocellular carcinoma (HCC) is the second leading cause of cancer re

150 Hepatocellular carcinoma (HCC) is the third most deadly cancer in the U

151 a acquired from patients with hepatocellular carcinoma (HCC) on tumors samples and their correspondin

152 locoregional therapy (LRT) on hepatocellular carcinoma (HCC) recurrence and survival after liver tran

153 e data from 242 patients with hepatocellular carcinoma (HCC) to search for gene signatures associated

154 OS) database in patients with hepatocellular carcinoma (HCC) who meet Milan criteria by imaging and u

155 eceptor FGFR4 by FGF19 drives hepatocellular carcinoma (HCC), a disease with few, if any, effective t

156 vide evidence that cells from hepatocellular carcinoma (HCC), a highly metastatic cancer, undergo epi

157 Hepatocellular carcinoma (HCC), a primary malignancy of the liver, is t

158 n mechanism in poor prognosis hepatocellular carcinoma (HCC), often associated with chronic hepatitis

159 In patients with advanced hepatocellular carcinoma (HCC), the multikinase inhibitor sorafenib is

160 epatosteatosis progressing to hepatocellular carcinoma (HCC).

161 implicated as an oncogene in hepatocellular carcinoma (HCC).

162 ciated with cancer, including hepatocellular carcinoma (HCC).

163 ase (MELD) at WL was >/=15 or hepatocellular carcinoma (HCC).

164 es are risk factors for human hepatocellular carcinoma (HCC).

165 ntain liver size and suppress hepatocellular carcinoma (HCC).

166 seases (CLDs) predisposing to hepatocellular carcinoma (HCC).

167 ved for treatment of advanced hepatocellular carcinoma (HCC).

168 common cause of cirrhosis and hepatocellular carcinoma (HCC).

169 nal analysis of patients with hepatocellular carcinoma (HCC).

170 or several cancers, including hepatocellular carcinoma (HCC).

171 More than 80% of hepatocellular carcinomas (HCCs) develop in fibrotic or cirrhotic liver

172 Hepatocellular carcinomas (HCCs) exhibit a diversity of molecular pheno

173 Global distribution of hepatocellular carcinomas (HCCs) is dominated by its incidence in devel

174 Human hepatocellular carcinomas (HCCs), which arise on a background of chroni

175 Colon carcinoma HCT 116 cells were cultured and grown into thr

176 ace of an HCV core-expressing hepatocellular carcinoma (HepG2) cell line or immortalized human hepato

177 e murine models of ovarian high grade serous carcinoma (HGSC) remain an important research tool.

178 opian tube among all cases.High-grade serous carcinomas (HGSCs) are associated with precursor lesions

179 Head and neck squamous cell carcinoma (HNSCC) accounts for nearly 90% of head and ne

180 locally advanced head and neck squamous cell carcinoma (HNSCC) and biomarkers that predict altered im

181 s (HPV)-positive head and neck squamous cell carcinoma (HNSCC) have better responses to radiotherapy

182 Head and neck squamous cell carcinoma (HNSCC) includes epithelial cancers of the ora

183 Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldw

184 mark of advanced head and neck squamous cell carcinoma (HNSCC).

185 Head and neck squamous cell carcinomas (HNSCC) exhibiting resistance to the EGFR-tar

186 Head and neck squamous cell carcinomas (HNSCCs) are refractory to therapeutic interv

187 is considered a precursor to invasive ductal carcinoma (IDC); however, approximately half of DCIS may

188 and outcomes of patients with hepatocellular carcinoma in Africa.

189 irus was the leading cause of hepatocellular carcinoma in Egypt (1054 [84%] of 1251 patients), and he

190 irradiation-mediated cutaneous squamous cell carcinoma in mice.

191 n papillomaviruses (betaPV) and keratinocyte carcinoma in OTRs.

192 case of endovascular treatment of renal cell carcinoma in patient with solitary kidney.

193 utic targets for prevention of squamous cell carcinoma in patients with Kindler syndrome.

194 ntraepithelial neoplasia (PIN) progressed to carcinoma in rats given neonatal low-dose BPA with adult

195 Young age (P < .001) and presence of ductal carcinoma in situ (DCIS) (HR, 2.15; 95% CI, 1.36-3.38; P

196 es with HER2-positive status in human ductal carcinoma in situ (DCIS) lesions and invasive breast can

197 ical presentation of that cancer, for ductal carcinoma in situ (DCIS), invasive breast cancer, and al

198 ce of any residual invasive cancer or ductal carcinoma in situ (DCIS).

199 grade 3 invasive ductal carcinoma and ductal carcinoma in situ (largest focus, 3.5 cm).

200 significantly reduced in precancerous ductal carcinoma in situ and all breast cancer subtypes.

201 nt breast cancers in each subset were ductal carcinoma in situ or stage I.

202 In cellular models of breast ductal carcinoma in situ, we reveal a link between filopodia fo

203 ed with increased risk of squamous cell lung carcinoma in the International Lung Cancer Consortium (N

204 velopment of an IPMN with HGD or an invasive carcinoma in the remnant pancreas.

205 an cervical cancer is the fourth most common carcinoma in women worldwide.

206 d by diethylnitrosamine (DEN) produced large carcinomas in all AhR-/- mice but mostly premalignant ad

207 tal of 45 cancers (33 invasive and 12 ductal carcinomas in situ) were diagnosed, 43 were seen with MR

208 k (hr) HPV-associated high-grade lesions and carcinomas in the anogenital region and oropharynx betwe

209 al neural autoantibody markers of small-cell carcinoma, including collapsin response-mediated protein

210 s with a resectable intrathoracic esophageal carcinoma, including the gastroesophageal junction tumor

211 Patients with multiple basal-cell carcinomas, including those with basal-cell nevus (Gorli

212 Metaplastic breast carcinoma is an aggressive form of invasive breast cance

213 Gastric stump carcinoma is an exceptional and poorly known long-term c

214 cRCC progression.The incidence of renal cell carcinoma is higher in males than in females due to the

215 acellular vesicle release from squamous cell carcinoma keratinocytes.

216 matched pericarcinomatous and hepatocellular carcinoma liver samples.

217 athy, and variceal bleeding), hepatocellular carcinoma, liver transplantation, and liver-related deat

218 in a murine model of OSA bearing Lewis lung carcinoma (LLC1) tumors.

219 20:4) were observed from CHB to cirrhosis to carcinoma; lower levels of lysoPC a C20:4 were found in

220 ze TLS formation in human lung squamous cell carcinoma (LSCC) and in an experimental model of lung TL

221 of tumor invasiveness of lung squamous cell carcinoma (LSCC).

222 ics included: adenocarcinoma, adenoid cystic carcinoma, meningioma, chondrosarcoma and fibromyxoid sa

223 broblasts (CAFs) are major components of the carcinoma microenvironment that promote tumor progressio

224 ard initial therapy in metastatic renal cell carcinoma (mRCC), but chronic dosing requires balancing

225 ne kinase inhibitor in metastatic renal cell carcinoma (mRCC).

226 of NEN in the direction of a neuroendocrine carcinoma (NEC - neuroednocrine carcinoma) with a poor p

227 nonoropharyngeal head and neck squamous cell carcinoma (non-OP HNSCC).

228 Nasopharyngeal carcinoma (NPC) is an aggressive head and neck cancer ch

229 ent in Chinese and Indonesian nasopharyngeal carcinoma (NPC) samples.

230 ffuse large B-cell lymphomas, nasopharyngeal carcinoma (NPC), and lymphomas that develop in organ tra

231 n patients with advanced non-small cell lung carcinoma (NSCLC), especially in those whose cancer tiss

232 als on secondary prevention of squamous cell carcinoma observed a reduction in cumulative tumor load,

233 copy-number variants in three squamous-cell carcinomas (oesophageal, head and neck and lung) signifi

234 sed, histologically confirmed, squamous cell carcinoma of the anus without metastatic disease from 59

235 ent of human cancer, including in urothelial carcinoma of the bladder (UCB).

236 al trial open to patients with biopsy-proven carcinoma of the esophagus.

237 apy in locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN).

238 irmed recurrent and metastatic squamous cell carcinoma of the head and neck after disease progression

239 s with recurrent or metastatic squamous cell carcinoma of the head and neck who progressed within 6 m

240 s with recurrent or metastatic squamous cell carcinoma of the head and neck, these data support nivol

241 s with recurrent or metastatic squamous cell carcinoma of the head and neck.

242 tments has been extrapolated from small cell carcinoma of the lung.

243 e patients with non-metastatic squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, o

244 ta-Analysis of Radiotherapy in squamous cell Carcinomas of Head and neck (MARCH) showed that altered

245 s (HPV)-negative oropharyngeal squamous cell carcinoma (OPSCC) has shown resistance to conventional c

246 ation therapy in oropharyngeal squamous cell carcinoma (OPSCC) that was determined to be relevant to

247 -CAG-NEMO vector developed no hepatocellular carcinoma or other major adverse effects 11 months after

248 ey area exists with regard to hepatocellular carcinoma or other tumour types in children.

249 Oral squamous cell carcinoma (OSCC) patients generally have a poor prognosi

250 but lower risks of LCIS and invasive ductal carcinomas (P for heterogeneity < 0.01).

251 acent normal tissues from six hepatocellular carcinoma patients.

252 rent in adenocarcinoma than in squamous cell carcinoma patients.

253 ce analysis of APC in at least 2 adenomas or carcinomas per patient.

254 tifying Nck as an important driver of breast carcinoma progression and metastasis, these results lay

255 protein-2 (EMP2) correlates with endometrial carcinoma progression and ultimately poor survival from

256 For the past decade, advanced renal cell carcinoma (RCC) has been at the forefront of oncologic i

257 Renal cell carcinoma (RCC) is a cancer with poor prognosis, and the

258 have identified six risk loci for renal cell carcinoma (RCC).

259 tients with melanoma (n = 16) and renal cell carcinoma (RCC; n = 15).

260 Squamous cell carcinoma-related oncogene (SCCRO)/DCUN1D1, a component

261 studies carried out in Germany: the Mammary Carcinoma Risk Factor Investigation (MARIE), a breast ca

262 ld induce apoptosis in human tongue squamous carcinoma SAS cells through mitochondrial pathway.

263 iators, but their functions in squamous cell carcinoma (SCC) are unclear.

264 strate for the first time that squamous cell carcinoma (SCC) EVs were enriched with the C-terminal fr

265 Anal squamous cell carcinoma (SCC) is associated with both human papillomav

266 port in a murine model of skin squamous cell carcinoma (SCC) that nuclear FAK regulates Runx1-depende

267 many human tumor types such as squamous cell carcinoma (SCC).

268 o act as a tumor suppressor in squamous cell carcinomas (SCCs).

269 enes involved in early phases of the adenoma-carcinoma sequence (such as, APC).

270 f orthologous genes with a human metaplastic carcinoma signature revealed a significant overlap of 87

271 Serous tubal intra-epithelial carcinoma (STIC) lesions are the putative precursor to H

272 Incidence of colorectal carcinoma subclassified by F nucleatum status in tumor t

273 erts growth inhibitory effects against colon carcinoma, suggesting a nutraceutical potential in the f

274 ver, the mechanisms underlying squamous cell carcinoma susceptibility are unclear.

275 lele actually protects against squamous cell carcinoma susceptibility.

276 lands-like C cells of the thyroid (medullary carcinoma), the parasympathetic and sympathetic system (

277 ll proliferation in esophageal squamous cell carcinoma through Orai1.

278 orods (GNRs-CD11b) are combined to treat the carcinoma tumor.

279 +/- 10.9) with 217 biopsy-proven renal cell carcinoma tumors treated with thermal ablation was condu

280 dult patients with oral cavity squamous cell carcinoma undergoing upfront surgical resection for cura

281 inary classification use cases: keratinocyte carcinomas versus benign seborrheic keratoses; and malig

282 bility of screening patients at risk of lung carcinoma via analysis of signals from online search act

283 Prior studies associating Merkel cell carcinoma viral status with prognosis have inconsistent

284 ificantly increased in patients with lobular carcinoma vs those with ductal carcinoma (adjusted odds

285 No evidence of hepatocellular carcinoma was detected.

286 trials for the treatment of small cell lung carcinoma, was synthesized using this strategy.

287 papilloma/well-differentiated squamous cell carcinoma (wdSCC), exhibiting p53 loss, increased prolif

288 progressive metastatic clear cell renal cell carcinoma were enrolled between September 2012 and April

289 howed that young age and high-grade invasive carcinoma were the most important risk factors for IBTR.

290 d leukemia, but is also detectable in breast carcinoma where its contributions are unexplored.

291 f prostate cancer tumors, and possibly other carcinomas where Sef is downregulated.

292 aged >/=18 years) with metastatic urothelial carcinoma who had progressed after platinum-based chemot

293 nic whites, whereas esophageal squamous cell carcinoma with risk factors of tobacco and alcohol is mo

294 ng, the development of Wnt activated mammary carcinomas with squamous differentiation was accompanied

295 uroendocrine carcinoma (NEC - neuroednocrine carcinoma) with a poor prognosis.

296 rberine suppresses the growth of human colon carcinoma xenograft in nude mice in an RXRalpha-dependen

297 ble and displays efficacy in a human ovarian carcinoma xenograft model.

298 acy in a human PTEN-deficient LNCaP prostate carcinoma xenograft tumor model.

299 delivery of decorin for treatment of breast carcinoma xenografts induces paternally expressed gene 3

300 d detectable clonogens in some SiHa cervical carcinoma xenografts, and in combination with gemcitabin